Management Team

Sudhir Agrawal, D. Phil. ׀ Chief Executive Officer and Chief Scientific Officer
Lou Arcudi ׀ Chief Financial Officer, Treasurer and Secretary
Alice S. Bexon, MBChB. ׀ Vice President, Clinical Development
Timothy M. Sullivan, Ph.D. ׀ Vice President, Development Programs
Ekambar R. Kandimalla, Ph.D. ׀ Vice President, Discovery
Steven J. Ritter, Ph.D., J.D. ׀ Vice President, Intellectual Property and Contracts
David M. Lough, Ph.D. ׀ Director, Business Development and Alliance Management
Frank Whalen, C.P.A. ׀ Controller

Timothy M. Sullivan, Ph.D. ׀ Vice President, Development Programs
Dr. Sullivan joined the Company in 2002 as Senior Director, Preclinical Drug Development and subsequently rose to his current position, Vice President, Development Programs. His prior professional experience includes a variety of technical management roles with pharmaceutical companies, including Purdue Pharma and Adria, contract research organizations, including Oread, Battelle and Roma Toxicology Centre, and in veterinary medicine at International Minerals & Chemical. Dr. Sullivan brings broad expertise in the design, execution, and application of nonclinical drug development programs. His publications, presentations, and reports submitted to regulatory authorities have covered topics in preclinical models of efficacy, safety pharmacology, pharmacokinetics/ADME, carcinogenicity, mutagenicity, and reproductive toxicology as well as general toxicology/pathology.

Dr. Sullivan earned his B.S. in Microbiology from Michigan State University. His graduate studies were at Purdue University, where he earned a M.S. degree in Health Physics and a Ph.D. in Toxicology.